Where Can I Buy Atrovent Nasal Spray Reviews

What is Atrovent Nasal Spray and how is it used?

Atrovent Nasal Spray is a prescription medicine used to treat the symptoms of seasonal allergies and runny nose caused by the common common cold. Atrovent Nasal Spray may exist used lonely or with other medications.

Atrovent Nasal Spray belongs to a class of drugs chosen Allergy, Intranasal.

Information technology is not known if Atrovent Nasal Spray is safe and effective in children younger than 5 years of age.

What are the possible side effects of Atrovent Nasal Spray?

Atrovent Nasal Spray may cause serious side effects including:

blurred vision,
tunnel vision,
middle pay,
seeing halos effectually lights,
nosebleeds,
astringent dry olfactory organ, and
painful or hard urination

Get medical assist right away, if y'all take any of the symptoms listed in a higher place.

The nearly common side effects of Atrovent Nasal Sprayinclude:

headache,
dry nose,
dry oral cavity or throat,
modest nosebleed,
sore throat,
blurred vision, and
unusual or unpleasant taste in the mouth

Tell the physician if you lot have any side consequence that bothers you or that does not go away.

These are non all the possible side effects of Atrovent Nasal Spray. For more information, ask your doctor or pharmacist.

Phone call your md for medical communication about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Description

The active ingredient in ATROVENT Nasal Spray is ipratropium bromide (equally the monohydrate). Information technology is an anticholinergic agent chemically described as 8-azoniabicyclo[iii.2.1] octane, iii-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-viii-(1-methylethyl)-, bromide monohydrate, (3-endo, viii-syn)-: a synthetic quaternary ammonium compound, chemically related to atropine. The structural formula is:

Atrovent® (ipratropium bromide) Structural Formula Illustration

C_xxH₃₀BrNO₃•H₂O ipratropium bromide Mol. Wt. 430.4

Ipratropium bromide is a white to fair crystalline substance, freely soluble in water and methanol, sparingly soluble in ethanol, and insoluble in non-polar media. In aqueous solution, it exists in an ionized state as a quaternary ammonium chemical compound.

ATROVENT Nasal Spray 0.06% is a metered-dose, manual pump spray unit of measurement which delivers 42 mcg ipratropium bromide (on an anhydrous basis) per spray (lxx μL) in an isotonic aqueous solution, pH-adjusted to iv.vii with muriatic acid and/or sodium hydroxide (if needed). Information technology likewise contains benzalkonium chloride, edetate disodium, sodium chloride, and purified water. Each bottle contains 165 sprays.

3 pharmacies near 11430 have coupons for Atrovent Nasal (Make Names:Atrovent Nasal Spray for 30ML of 0.03%)

INDICATIONS

ATROVENT Nasal Spray 0.06% is indicated for the symptomatic relief of rhinorrhea associated with the common common cold or seasonal allergic rhinitis for adults and children historic period 5 years and older. ATROVENT Nasal Spray 0.06% does non relieve nasal congestion or sneezing associated with the common common cold or seasonal allergic rhinitis. The safety and effectiveness of the use of Atrovent® (ipratropium bromide) Nasal Spray 0.06% across iv days in patients with the common common cold or beyond iii weeks in patients with seasonal allergic rhinitis has not been established.

SLIDESHOW

Could I Exist Allergic? Notice Your Allergy Triggers Come across Slideshow

DOSAGE AND ADMINISTRATION

For Symptomatic Relief of Rhinorrhea Associated with the Mutual Common cold

The recommended dose of ATROVENT Nasal Spray 0.06% is 2 sprays (84 mcg) per nostril three or four times daily (full dose 504 to 672 mcg/solar day) in adults and children age 12 years and older. Optimum dosage varies with response of the individual patient. The recommended dose of ATROVENT Nasal Spray 0.06% for children historic period five-11 years is two sprays (84 mcg) per nostril three times daily (total dose of 504 mcg/day).

The safety and effectiveness of the employ of ATROVENT Nasal Spray 0.06% beyond four days in patients with the common cold have non been established.

For Symptomatic Relief of Rhinorrhea Associated with Seasonal Allergic Rhinitis

The recommended dose of ATROVENT Nasal Spray 0.06% is two sprays (84 mcg) per nostril four times daily (total dose 672 mcg/day) in adults and children age five years and older.

The safety and effectiveness of the use of ATROVENT Nasal Spray 0.06% beyond three weeks in patients with seasonal allergic rhinitis accept not been established.

Initial pump priming requires seven sprays of the pump. If used regularly every bit recommended, no further priming is required. If not used for more than than 24 hours, the pump will crave two sprays, or if not used for more than seven days, the pump will require seven sprays to reprime. Avoid spraying into eyes.

HOW SUPPLIED

ATROVENT Nasal Spray 0.06% is supplied in a white high density polyethylene (HDPE) bottle fitted with a metered nasal spray pump, a green safety clip to prevent adventitious discharge of the spray, and a clear plastic dust cap. It contains 16.six thousand of product formulation, 165 sprays, each delivering 42 mcg of ipratropium bromide per spray (70 μL), or 10 days of therapy at the maximum recommended dose (two sprays per nostril four times a twenty-four hours) (NDC 0597-0086-76).

Store tightly airtight at 25°C (77°F); excursions permitted to 15°- xxx°C (59°-86°F) [run into USP Controlled Room Temperature]. Avoid freezing. Keep out of reach of children. Exercise not spray in the eyes.

Accost medical inquiries to: http://us.boehringer-ingelheim.com, (800) 542-6257 or (800) 459-9906 TTY.

Patients should be reminded to read and follow the accompanying "Patient's Instructions for Use", which should exist dispensed with the product.

Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877 U.s.a.. Revised: Mar 2011

Side Effects & Drug Interactions

SIDE EFFECTS

Adverse reaction information on ATROVENT Nasal Spray 0.06% in patients with the common cold was derived from ii multicenter, vehicle-controlled clinical trials involving ane,276 patients (195 patients on ATROVENT Nasal Spray 0.03%, 352 patients on ATROVENT Nasal Spray 0.06%, 189 patients on ATROVENT Nasal Spray 0.12%, 351 patients on vehicle and 189 patients receiving no handling).

Table 1 shows adverse events reported for patients who received ATROVENT Nasal Spray 0.06% at the recommended dose of 84 mcg per nostril, or vehicle, administered three or four times daily, where the incidence is 1% or greater in the ATROVENT group and college in the ATROVENT group than in the vehicle group.

Tabular array 1 % of Patients with Common Common cold Reporting Events1

	Atrovent® (ipratropium bromide) Nasal Spray 0.06%	Vehicle Control
No. of Patients	352	351
Epistaxis^two	8.two%	2.three%
Nasal Dryness	iv.eight%	two.8%
Dry Mouth/Throat	1.4%	0.three%
Nasal Congestion	1.1%	0.0%
¹ This table includes adverse events for which the incidence was 1% or greater in the ATROVENT grouping and higher in the ATROVENT group than in the vehicle group. ² Epistaxis reported by 5.4% of ATROVENT patients and 1.four% of vehicle patients, blood-tinged nasal mucus by 2.8% of ATROVENT patients and 0.9% of vehicle patients.

ATROVENT Nasal Spray 0.06% was well tolerated by virtually patients. The well-nigh oft reported adverse events were transient episodes of nasal dryness or epistaxis. The majority of these adverse events (96%) were mild or moderate in nature, none was considered serious, and none resulted in hospitalization. No patient required treatment for nasal dryness, and only iii patients (<1%) required treatment for epistaxis, which consisted of local application of pressure or a moisturizing agent (e.g., petroleum jelly). No patient receiving ATROVENT

Nasal Spray 0.06% was discontinued from the trial due to either nasal dryness or bleeding. Adverse events reported by less than one% of the patients receiving ATROVENT Nasal Spray 0.06% during the controlled clinical trials that are potentially related to ATROVENT'southward local effects or systemic anticholinergic effects include: gustation perversion, nasal burning, conjunctivitis, cough, dizziness, hoarseness, palpitation, pharyngitis, tachycardia, thirst, tinnitus, and blurred vision. No controlled trial was conducted to accost the relative incidence of adverse events for three times daily versus iv times daily therapy.

Nasal adverse events seen in the clinical trial with seasonal allergic rhinitis (SAR) patients (see Table 2) were similar to those seen in the cold trials. Additional events were reported at a higher rate in the SAR trial due in function to the longer elapsing of the trial and the inclusion of Upper Respiratory Tract Infection (URI) as an agin effect. In common cold trials, URI was the disease under study and not an adverse event.

Table 2 % of Patients with SAR Reporting Events¹

	Atrovent® (ipratropium bromide) Nasal Spray 0.06%	Vehicle Control
No. of Patients	218	211
Epistaxis²	vi.0%	3.3%
Pharyngitis	5.0%	3.8%
URI	5.0%	iii.3%
Nasal Dryness	4.six%	0.9%
Headache	four.i%	0.5%
Dry Mouth/Throat	4.i%	0.0%
Taste Perversion	iii.7%	1.four%
Sinusitis	2.8%	2.8%
Pain	one.eight%	0.9%
Diarrhea	1.eight%	0.five%
¹ This table includes adverse events for which the incidence was ane% or greater in the ATROVENT group and higher in the ATROVENT group than in the vehicle group. ⁱⁱ Epistaxis reported by 3.7% of ATROVENT patients and 2.4% of vehicle patients, blood-tinged nasal mucus by two.3% of ATROVENT patients and i.ix% of vehicle patients.

There were no reports of allergic-type reactions in the controlled clinical common cold and SAR trials.

Post-Marketing Experience

Allergic-blazon reactions such as skin rash, angioedema, including that of the pharynx, tongue, lips and face, generalized urticaria (including giant urticaria), laryngospasm, and anaphylactic reactions have been reported with ATROVENT Nasal Spray 0.06% and for other ipratropium bromide-containing products, with positive rechallenge in some cases.

Boosted side furnishings identified from the published literature and/or post-marketing surveillance on the apply of ipratropium bromide-containing products (singly or in combination with albuterol), include: urinary retentivity, prostatic disorders, mydriasis, cases of precipitation or worsening of narrow-angle glaucoma, acute center hurting, ocular irritation, wheezing, dryness of the oropharynx, tachycardia, edema, gastrointestinal distress (diarrhea, nausea, vomiting), bowel obstruction, constipation, nasal discomfort, throat irritation, hypersensitivity, accommodation disorder, intraocular pressure increased, glaucoma, halo vision, conjunctival hyperaemia, corneal edema, heart rate increased, bronchospasm, pharyngeal edema, gastrointestinal motility disorder, oral cavity edema, stomatitis, and pruritus.

After oral inhalation of ipratropium bromide in patients suffering from COPD/Asthma supraventricular tachycardia and atrial fibrillation have been reported.

DRUG INTERACTIONS

No controlled clinical trials were conducted to investigate potential drug-drug interactions. In that location is potential for an additive interaction with other concomitantly administered medications with anticholinergic backdrop, including ATROVENT for oral inhalation.

QUESTION

Allergies tin best be described as: See Answer

WARNINGS

Immediate hypersensitivity reactions may occur after administration of ipratropium bromide, equally demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema.

PRECAUTIONS

General

Effects Seen with Anticholinergic Drugs: ATROVENT Nasal Spray (ipratropium bromide nasal spray) 0.03% should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or bladder neck obstruction, especially if they are receiving an anticholinergic by another route.
Employ in Hepatic or Renal Disease: ATROVENT Nasal Spray (ipratropium bromide nasal spray) 0.03% has not been studied in patients with hepatic or renal insufficiency. Information technology should exist used with caution in those patient populations.

Information for Patients

Patients should be brash that temporary blurring of vision, precipitation or worsening of narrow-bending glaucoma, mydriasis, increased intraocular pressure, acute eye pain or discomfort, visual halos or colored images in association with reddish optics from conjunctival and corneal congestion may issue if ATROVENT Nasal Spray 0.03% comes into direct contact with the eyes. Patients should be instructed to avoid spraying ATROVENT Nasal Spray (ipratropium bromide nasal spray) 0.03% in or effectually their eyes. Patients who experience centre pain, blurred vision, excessive nasal dryness, or episodes of nasal bleeding should exist instructed to contact their dr.. To ensure proper dosing, patients should be brash not to alter the size of the nasal spray opening. Patients should be reminded to carefully read and follow the accompanying Patient's Instructions for Apply.

Carcinogenesis, Mutagenesis, Harm of Fertility

2-year oral carcinogenicity studies in rats and mice have revealed no carcinogenic activity at doses upwardly to 6 mg/kg. This dose corresponds in rats and mice to approximately 190 and 95 times the maximum recommended daily intranasal dose in adults, respectively, and approximately 110 and 55 times the maximum recommended daily intranasal dose in children, respectively, on a mg/m² basis. Results of various mutagenicity studies (Ames test, mouse dominant lethal test, mouse micronucleus test, and chromosome aberration of bone marrow in Chinese hamsters) were negative.

Fertility of male or female rats at oral doses up to 50 mg/kg (approximately i,600 times the maximum recommended daily intranasal dose in adults on a mg/m² ground) was unaffected by ipratropium bromide administration. At an oral dose of 500 mg/kg (approximately 16,000 times the maximum recommended daily intranasal dose in adults on a mg/m² ground), ipratropium bromide produced a decrease in the conception charge per unit.

Pregnancy

Teratogenic Effects: Pregnancy Category B.

Oral reproduction studies were performed at doses of x mg/kg in mice, 1000 mg/kg in rats and 125 mg/kg in rabbits. These doses correspond, in each species, respectively, to approximately 160, 32,000, and 8,000 times the maximum recommended daily intranasal dose in adults on a mg/m² basis. Inhalation reproduction studies were conducted in rats and rabbits at doses of 1.5 and ane.8 mg/kg, respectively, (approximately 50 and 120 times, respectively, the maximum recommended daily intranasal dose in adults on a mg/m² basis). These studies demonstrated no evidence of teratogenic effects every bit a result of ipratropium bromide. At oral doses 90 mg/kg and higher up in rats (approximately 2,900 times the maximum recommended daily intranasal dose in adults on a mg/chiliad² basis) embryotoxicity was observed as increased resorption. This effect is non considered relevant to human use due to the large doses at which it was observed and the difference in route of assistants. However, no adequate or well controlled studies accept been conducted in pregnant women. Because animal reproduction studies are not ever predictive of human response, Atrovent® (ipratropium bromide) Nasal Spray 0.03% should be used during pregnancy only if clearly needed.

Nursing Mothers

It is known that some ipratropium bromide is systemically captivated following nasal administration; however the portion which may exist excreted in human milk is unknown. Although lipid-insoluble fourth cations laissez passer into breast milk, the minimal systemic absorption makes it unlikely that ipratropium bromide would attain the infant in an amount sufficient to cause a clinical upshot. However, because many drugs are excreted in man milk, caution should exist exercised when ATROVENT Nasal Spray (ipratropium bromide nasal spray) 0.03% is administered to a nursing female parent.

Pediatric Use

The safe of Atrovent® (ipratropium bromide) Nasal Spray 0.03% at a dose of two sprays (42 mcg) per nostril 2 or iii times daily (full dose 168 to 252 mcg/day) has been demonstrated in 77 pediatric patients 6-12 years of historic period in placebo-controlled, 4-week trials and in 55 pediatric patients in active-controlled, 6 calendar month trials. The effectiveness of ATROVENT Nasal Spray (ipratropium bromide nasal spray) 0.03% for the handling of rhinorrhea associated with allergic and nonallergic perennial rhinitis in this pediatric age group is based on an extrapolation of the demonstrated efficacy of ATROVENT Nasal Spray (ipratropium bromide nasal spray) 0.03% in adults with these conditions and the likelihood that the disease class, pathophysiology, and the drug'south effects are substantially similar to that of the adults. The recommended dose for the pediatric population is based on within and cross-written report comparisons of the efficacy of ATROVENT Nasal Spray 0.03% in adults and pediatric patients and on its safety profile in both adults and pediatric patients. The rubber and effectiveness of ATROVENT Nasal Spray 0.03% in patients under 6 years of age have not been established.

Overdosage & Contraindications

OVERDOSE

Acute overdosage past intranasal administration is unlikely since ipratropium bromide is non well absorbed systemically later on intranasal or oral administration. Post-obit administration of a twenty mg oral dose (equivalent to ingesting more than two bottles of Atrovent® (ipratropium bromide) Nasal Spray 0.06%) to 10 male volunteers, no change in middle rate or blood pressure was noted. Post-obit a 2 mg intravenous infusion over xv minutes to the same 10 male volunteers, plasma ipratropium concentrations of 22-45 ng/mL were observed (>100 times the concentrations observed post-obit intranasal assistants). Following intravenous infusion these 10 volunteers had a mean increase of heart rate of 50 bpm and less than 20 mmHg change in systolic or diastolic blood pressure at the fourth dimension of height ipratropium levels.

CONTRAINDICATIONS

ATROVENT Nasal Spray 0.06% is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, or to any of the other ingredients.

CLINICAL PHARMACOLOGY

Mechanism Of Action

Ipratropium bromide is an anticholinergic (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally-mediated reflexes past antagonizing the action of acetylcholine, the transmitter amanuensis released at the neuromuscular junctions in the lung. In humans, ipratropium bromide has anti-secretory properties and, when applied locally, inhibits secretions from the serous and seromucous glands lining the nasal mucosa. Ipratropium bromide is a quaternary amine that minimally crosses the nasal and gastrointestinal membranes and the claret-brain barrier, resulting in a reduction of the systemic anticholinergic furnishings (e.g., neurologic, ophthalmic, cardiovascular, and gastrointestinal effects) that are seen with tertiary anticholinergic amines.

Pharmacokinetics

Absorption

Ipratropium bromide is poorly absorbed into the systemic apportionment following oral administration (ii-3%). Less than 20% of an 84 mcg per nostril dose was absorbed from the nasal mucosa of normal volunteers, induced-cold developed volunteers, naturally acquired common common cold pediatric patients, or perennial rhinitis adult patients.

Distribution

Ipratropium bromide is minimally bound (0 to 9% in vitro) to plasma albumin and α1-acid glycoprotein. Its blood/plasma concentration ratio was estimated to be about 0.89. Studies in rats have shown that ipratropium bromide does not penetrate the blood-brain barrier.

Metabolism

Ipratropium bromide is partially metabolized to ester hydrolysis products, tropic acid, and tropane. These metabolites appear to be inactive based on in vitro receptor analogousness studies using rat brain tissue homogenates.

Elimination

After intravenous administration of two mg ipratropium bromide to x salubrious volunteers, the terminal half-life of ipratropium bromide was approximately 1.6 hours. The total body clearance and renal clearance were estimated to be 2,505 and one,019 mL/min, respectively. The corporeality of the total dose excreted unchanged in the urine (Ae) within 24 hours was approximately one-half of the administered dose.

Pediatrics

Following assistants of 84 mcg of ipratropium bromide per nostril three times a day in patients 5-eighteen years old (northward=42) with a naturally caused common common cold, the hateful corporeality of the total dose excreted unchanged in the urine of 7.8% was comparable to 84 mcg per nostril iv times a day in an adult induced common cold population (n=22) of 7.3 to 8.i%. Plasma ipratropium concentrations were relatively depression (ranging from undetectable upward to 0.62 ng/mL). No correlation of the amount of the total dose excreted unchanged in the urine (Ae) with age or gender was observed in the pediatric population.

Special Populations

Gender does not appear to influence the assimilation or excretion of nasally administered ipratropium bromide. The pharmacokinetics of ipratropium bromide have not been studied in patients with hepatic or renal insufficiency or in the elderly.

Drug-Drug Interactions

No specific pharmacokinetic studies were conducted to evaluate potential drug-drug interactions.

Pharmacodynamics

In 2 single-dose trials (n=17), doses upwards to 336 mcg of ipratropium bromide did non significantly affect pupillary diameter, middle rate, or systolic/diastolic blood pressure. Similarly, Atrovent® (ipratropium bromide) Nasal Spray 0.06% in adult patients (n=22) with induced-colds (84 mcg/nostril 4 times a day) and in pediatric patients (n=45) with naturally caused mutual common cold (84 mcg/nostril three times a twenty-four hours) had no significant effects on pupillary diameter, center rate, or systolic/diastolic blood force per unit area.

Controlled clinical trials demonstrated that intranasal fluorocarbon-propelled ipratropium bromide does not alter physiologic nasal functions (due east.g., sense of smell, ciliary beat frequency, mucociliary clearance, or the air workout capacity of the olfactory organ).

Clinical Trials

The clinical trials for ATROVENT Nasal Spray 0.06% were conducted in patients with rhinorrhea associated with naturally occurring common colds. In two controlled four day comparisons of ATROVENT Nasal Spray 0.06% (84 mcg per nostril, administered 3 or four times daily; due north=352) with its vehicle (n=351), there was a statistically significant reduction of rhinorrhea, as measured by both nasal discharge weight and the patients' subjective assessment of severity of rhinorrhea using a visual analog scale. These significant differences were axiomatic within one hour post-obit dosing. In that location was no issue of ATROVENT Nasal Spray 0.06% on degree of nasal congestion or sneezing. The response to ATROVENT Nasal Spray 0.06% did not announced to be afflicted by age or gender. No controlled clinical trials directly compared the efficacy of three times daily versus four times daily handling.

One clinical trial was conducted with ATROVENT Nasal Spray 0.06%, administered four times daily for iii weeks, in 218 patients with rhinorrhea associated with Seasonal Allergic Rhinitis (SAR), compared to its vehicle in 211 patients. Patients in this trial were adults and adolescents 12 years of historic period and above. ATROVENT Nasal Spray 0.06% was significantly more than effective in reducing the severity and duration of rhinorrhea over the three weeks of the written report, as measured by daily patient symptom scores. There was no difference between handling groups in the effect on nasal congestion, sneezing or itching optics.

PATIENT Information

Patient's Instructions for Use

Atrovent®
(ipratropium bromide) Nasal Spray 0.06% 42 mcg/spray

Read consummate instructions carefully before using.

In lodge to ensure proper dosing, do not endeavour to change the size of the spray opening.

ATROVENT Nasal Spray 0.06% is indicated for the symptomatic relief of rhinorrhea (runny nose) associated with the common cold or seasonal allergic rhinitis for adults and children age v years and older. ATROVENT Nasal Spray 0.06% does not save nasal congestion or sneezing associated with the common cold or seasonal allergic rhinitis. Do not use ATROVENT Nasal Spray 0.06% for longer than four days for a common common cold or three weeks for seasonal allergic rhinitis unless instructed by your physician.

Read complete instructions advisedly and employ merely as directed.

To Utilize:

ane. Remove the clear plastic grit cap and the green safety clip from the nasal spray pump (Figure i). The safety clip prevents the accidental belch of the spray in your pocket or purse.

Figure 1

Remove the clear plastic dust cap - Illustration

two. The nasal spray pump must be primed earlier Atrovent^® (ipratropium bromide) Nasal Spray 0.06% is used for the first time. To prime the pump, hold the bottle with your thumb at the base and your index and middle fingers on the white shoulder area. Make sure the bottle points upright and away from your eyes. Press your thumb firmly and quickly against the bottle seven times (Effigy two). The pump is now primed and can be used. Your pump should not have to exist reprimed unless you have not used the medication for more than than 24 hours; repriming the pump will only require two sprays. If you accept non used your nasal spray for more than seven days, repriming the pump will require 7 sprays.

Figure two

Priming the pump - Illustration

three. Before using ATROVENT Nasal Spray 0.06%, blow your nose gently to clear your nostrils if necessary.

iv. Shut one nostril past gently placing your finger against the side of your olfactory organ, tilt your head slightly forwards and, keeping the bottle upright, insert the nasal tip into the other nostril (Figure 3). Point the tip toward the back and outer side of the nose.

Figure 3

Positioning the nozzle in the nose - Illustration

v. Press firmly and quickly up with the thumb at the base while holding the white shoulder portion of the pump between your index and eye fingers. Post-obit each spray, sniff securely and breathe out through your oral cavity.

6. After spraying the nostril and removing the unit, tilt your head backwards for a few seconds to let the spray spread over the back of the nose.

vii. Echo steps 4 through six in the aforementioned nostril.

viii. Repeat steps 4 through 7 in the other nostril (i.e., 2 sprays per nostril).

ix. Supplant the articulate plastic dust cap and safety prune.

x. At some time earlier the medication is completely used up, you should consult your physician or pharmacist to make up one's mind whether a refill is needed. You should not accept extra doses or stop using Atrovent^® (ipratropium bromide) Nasal Spray 0.06% without consulting your physician.

To Clean:

If the nasal tip becomes clogged, remove the clear plastic dust cap and safe clip. Hold the nasal tip under running, warm tap water (Figure 4) for about a infinitesimal. Dry the nasal tip, reprime the nasal spray pump (step 2 above), and replace the plastic grit cap and safety clip.

Figure 4

Cleaning the nozzle tip - Illustration

Circumspection:

ATROVENT Nasal Spray 0.06% is intended to relieve your rhinorrhea (runny nose) with regular apply. It is therefore of import that you use ATROVENT Nasal Spray 0.06% as prescribed by your physician. For most patients, some improvement in runny nose is credible following the outset dose of treatment with ATROVENT Nasal Spray 0.06%. Do non use ATROVENT Nasal Spray 0.06% for longer than four days for your common cold or 3 weeks for seasonal allergic rhinitis unless instructed by your physician.

Practise not spray ATROVENT Nasal Spray 0.06% in your eyes. Should this occur, immediately flush your eye with cool tap water for several minutes. If you accidentally spray ATROVENT Nasal Spray 0.06% in your optics, yous may feel a temporary blurring of vision, visual halos or colored images in clan with cerise eyes from conjunctival and corneal congestion, evolution or worsening of narrow-angle glaucoma, pupil dilation, or acute eye pain/discomfort, and increased sensitivity to calorie-free, which may last a few hours. Should astute eye hurting or blurred vision occur, contact your physician.

Should yous experience excessive nasal dryness or episodes of nasal haemorrhage, contact your medico.

If you take glaucoma or difficulty urinating due to an enlargement of the prostate, exist sure to tell your medico prior to using ATROVENT Nasal Spray 0.06%.

If you are pregnant or you are breast feeding your baby, exist sure to tell your physician prior to using ATROVENT Nasal Spray 0.06%.

Address medical inquiries to: http://us.boehringer-ingelheim.com, (800) 542-6257 or (800) 459-9906 TTY.

Store tightly airtight at 25°C (77°F); excursions permitted to xv°-thirty°C (59°-86°F) [meet USP Controlled Room Temperature]. Avoid freezing. Keep out of reach of children.

From

FDA Logo

Report Bug to the Nutrient and Drug Administration

You lot are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

piercesagifen1964.blogspot.com

Source: https://www.rxlist.com/atrovent-nasal-spray-drug.htm